A collection of features and news articles published in ASH Clinical News related to myelodysplastic syndromes and myeloproliferative neoplasms.
New Prognostic Model Outperforms Established Predictive Models in MDS
In a study published in the Journal of Clinical Oncology, researchers reported that a newly developed personalized prediction model comprising clinical and genomic data...
Reduced-Intensity Conditioning Transplant Superior to Continuous 5-Azacitidine in Older Patients With MDS
In older patients with advanced myelodysplastic syndromes (MDS), reduced-intensity conditioning allogeneic hematopoietic cell transplantation (HCT) improved event-free survival (EFS) compared with continuous 5-azacitidine therapy....
Rusfertide Helps Patients With Polycythemia Vera Avoid Phlebotomy
Patients with polycythemia vera (PV) who received rusfertide were able to avoid therapeutic phlebotomy for seven months, even among those with high-risk disease, according...
Avapritinib Approved for Advanced Systemic Mastocytosis
The FDA has approved avapritinib for the treatment of adult patients with advanced systemic mastocytosis (SM), SM with an associated hematologic neoplasm, and mast...
Exploring Venetoclax Plus Azacitidine in CMML and MPNs
The combination of the BCL2 inhibitor venetoclax and the hypomethylating agent azacitidine has been established as a standard of care for patients with acute...
Survival Outcomes After HLA-Haploidentical Relative Versus Matched Unrelated Donor Transplant in Acute Leukemias and...
In patients with acute leukemias or myelodysplastic syndromes (MDS), those who underwent haploidentical relative hematopoietic cell transplantation (haploHCT) had higher rates of grade 3-4...
Evaluating Enasidenib, With or Without Azacitidine, in Patients with IDH2-Mutated MDS
Enasidenib was had a tolerable safety profile and showed promising clinical activity in patients with IDH2-mutated, high-risk myelodysplastic syndromes (MDS), according to results from...
PATHFINDER: Avapritinib Induces Rapid Responses in Advanced Systemic Mastocytosis
Three-quarters of patients with advanced systemic mastocytosis (SM) responded to treatment with the oral KIT D816V inhibitor avapritinib, according to interim results from the...
Four of a Kind?
Soon, there may be as many as four JAK inhibitors available for patients with myelofibrosis.
For many of his patients with myelofibrosis, ruxolitinib has been...
How Do Patients With Myeloproliferative Neoplasms Fare After COVID-19 Infection?
Two analyses from the MPN-COVID study from a group of researchers led by Tiziano Barbui, MD, of the United Hospitals of Bergamo in Italy,...
